Ten post jest także dostępny w języku: polski
Medinice, a Polish company developing innovative projects for cardiology and cardiac surgery, has signed a preliminary agreement for the purchase of shares in a company which holds rights to globally patented cardiac surgery technology. The promised agreement is to be signed by the end of March 2021.
Medinice invests in a company with a patent
Medinice will invest in shares in the company that owns the innovative project. The deadline for concluding the promised agreement is 31 March 2021. It is a clamp for closing the left atrial appendage of the heart. The effectiveness of the technology has been confirmed in animal preclinical tests. Currently, the project is the subject of clinical trials on humans.
The transaction involves three stages. The first is a cash payment of PLN 2.11m. The second is a payment in the form of issue of 72,204 subscription warrants entitling to take up the same number of J series shares. The third is an increase in the company’s capital by PLN 690,000. As a result of the transaction, the issuer will hold 40% of the capital and 40% of the votes at the company’s general meeting of shareholders together with the right to 50% of the company’s dividend.
December: WSE debut and awarded grant
Medinice debuted on the WSE main market in December 2020. Earlier, in November 2020, there were changes in the company’s management board. Namely, the company’s Supervisory Board appointed Arkadiusz Dorynek and Piotr Wiliński as Vice Presidents of the Management Board. The term of both men expires on 19 November 2022.
It is worth mentioning that on 30 December 2020, Medinice also received from the National Centre for Research and Development (NCBiR) a signed agreement on co-financing of the project “EP Bioptom – Electrophysiological diagnostic electrode for endomyocardial biopsy”. The value of the project is nearly PLN 5.4m, of which over PLN 3.9m is a subsidy.
Cardiology is an important field of medicine, more on this subject can be found here.